Has The Age Of Antisense Oligonucleotides Finally Arrived?

By Sankha Pattanayak, Ph.D., Principal Investigator, Chemical Development - Oligonucleotides PRD, Syngene International Ltd.

Antisense oligonucleotides (ASOs) represent a pivotal shift in modern medicine, bridging the gap between small molecules and biologics. By leveraging predictable Watson-Crick base pairing to bind specific RNA sequences, these short, synthetic strands alter faulty protein expression at the genomic level. This elegant approach unlocks therapeutic avenues for previously undruggable genetic disorders, viral infections, and cancers. While historic hurdles like rapid cellular degradation and off-target toxicity limited early clinical success, advanced chemical modifications—such as morpholinos and locked nucleic acids—dramatically enhance stability, potency, and nuclease resistance. As clinical pipelines expand globally, mastering these evolving mechanisms of action, from steric blocking to alternative splicing, is vital for navigating the future of targeted therapeutics.

Explore the full viewpoint to examine the chemical innovations driving this scientific renaissance.